Figure 6个  Table 2个
    • Variables Total patients HIV positive Chi square P value
      Gender 0.018 0.894
       Female 1675 40 (2.4%)
       Male 1176 29 (2.5%)
      Ethnicity 4.201 0.122
       Lao Loum 2445 65 (2.7%)
       Lao Soung 264 3 (1.1%)
       Lao Theung 142 1 (0.7%)
      Domiciles of origin 14.514 0.024
       Vientiane Capital 1682 54 (3.2%)
       Khammouan 72 2 (2.8%)
       Bolikamxai 517 10 (1.9%)
       Xaignabouli 57 1 (1.8%)
       Xiangkhoang 129 1 (0.8%)
       Vientiane 209 1 (0.5%)
       Other provinces* 185 0
      *Attapu, Bokèo, Champasak, Houaphan, Louang Namtha, Louangphrabang, Oudômxai, Phoôngsali, Salavan, Savannakhet, Xékong

      Table 1.  The prevalence of HIV among hospital patients in Vientiane Prefecture of Laos.

    • Samples NRTI NNRTI PI IN
      Mutations Resistant Mutations Resistant Mutations Resistant Mutations Resistant
      VT36M3933 M184I ABC (L), FTC (H), 3TC (H) E138K, G190E EFV (H), ETR (M), NVP (H), RPV (H) D30N, M46I, G48R, G73S ATV/r (L), FPV/r (L), IDV/r (L), LPV/r (L), NFV (H), SQV/ r (L)
      VT38M3815 A62V, V75I, F116Y, Q151M, M184V ABC (H), AZT (H), D4T (H), DDI (H), FTC (H), 3TC (H), TDF (M) Y181I EFV (M), ETR (H), NVP (H), RPV (H)
      VT42M2998 M184I ABC (L), FTC (H), 3TC (H) G190S, M230I EFV (H), ETR (L), NVP (H), RPV (M)
      VT37F3781 T215A AZT (L), D4T (L)
      VT27F3026 E138G RPV (L) M46I NFV (M),
      BL50F5250 E138K RPV (M)
      VT30F3147 G140R, G163R EVG (L), RAL (L)
      NRTI Nucleoside reverse transcriptase inhibitors, NNRTI non-nucleoside reverse transcriptase inhibitors, IN integrase inhibitors, PI protease inhibitors, L low level resistance, M intermediate resistance, H high-level resistance, ABC abacavir, FTC emtricitabine, 3TC lamivudine, AZT zidovudine, D4T stavudine, DDI didanosine, TDF tenofovir, EFV efavirenz, ETR etravirine, NVP nevirapine, RPV rilpivirine, ATV/r atazanavir/r, FPV/r fosamprenavir/r, IDV/r indinavir/r, LPV/r lopinavir/r, NFV nelfinavir, SQV/r saquinavir/r, EVG elvitegravir, RAL raltegravir

      Table 2.  The drug resistance mutations of HIV sequences amplified from patients in Vientiane Capital, Laos.